LW231
PreclinicalSmall molecule
LW231 is one of 3 small molecule programs targeting Chronic HBV Infection. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Chronic HBV Infection
#DrugCompanyPhaseTrials
1Methylthioninium Chloride
PProvepharm SAS
Phase 2
Hepsera
GileadPreclinical
LW231
SShanghai Longwood Biopharmaceuticals Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LW231. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details